BLAINJECTIONINJECTABLEPriority Review
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADUHELM (aducanumab-avwa) is a monoclonal antibody approved by the FDA in June 2021 for early Alzheimer's disease. The drug targets amyloid-beta pathology in the brain via intravenous infusion. It represents a disease-modifying approach to cognitive decline in preclinical and mild cognitive impairment stages.
Peak
Peak lifecycle positioning suggests stable commercial operations, but limited publicly available spending data indicates market adoption challenges that may constrain team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
Started Nov 2021
29 enrolled
Alzheimers Disease
Career Relevance
ADUHELM positions are scarce (0 linked jobs in data), reflecting limited commercial scale and market adoption challenges. Career roles focus heavily on managed care negotiation, physician education, and patient access navigation rather than rapid expansion teams.
Brand Manager
Worked on ADUHELM at Biogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.